headerheaderheader
home

Meet the Oleander Team

Management Team

Dennis Paul, Ph.D.
Co-Founder and Managing Member / Chief Science Officer

Dr. Paul is Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center in New Orleans. He received his Ph.D. from the University of British Columbia and completed Post-Doctoral training at the Memorial Sloan-Kettering Cancer Center. Dr. Paul's research has contributed to the understanding of opioid pharmacology and drug-drug interactions. He has served on scientific advisory boards for Xanadyne Pharmaceuticals and St. Charles Pharmaceuticals.


Harry J. Gould, III, M.D., Ph.D.
Co-Founder and Managing Member / Chief Medical Officer

Dr. Gould is Professor of Neurology and Neuroscience; received his Ph.D. from Brown University, his M.D. from LSU Health Sciences Center, and is board certified in Neurology and Pain Management. Dr. Gould's early research contributed to understanding the organization of sensory/motor systems in the cerebral cortex. He has served on scientific advisory boards for Elan Pharmaceuticals, Parke-Davis, Pfizer, Ortho-McNeil Pharmaceuticals, Novartis Pharmaceuticals, Alpharma, Inc. (currently King Pharmaceuticals), Endo Pharmaceuticals, Gilead Sciences, Inc. and Depomed, Inc.

Drs. Paul and Gould have had a long and productive collaboration that has focused on general concepts and biological principles related to the role played by sodium channels in the mechanisms responsible for pain and diabetic peripheral neuropathy that has led to the treatment of malignancy.


Paige R. Miller, J.D.
Managing Member / President

Ms. Miller is a graduate of Yale Law School and has served as Commissioner and President of the Port of Seattle, one of the nation's largest combined airport and seaport authorities. She has been instrumental in developing and serving as Chair of the Board of Port Jobs, a non-profit enterprise in Seattle and was a Legislative Analyst for The City of Seattle. Previously she was in private practice in Seattle and in Philadelphia. She is currently the Executive Director of the Arboretum Foundation. She brings the company expertise in fundraising, strategic planning, governance, and external relations.


Hank Mills
Managing Member / Chief Business Officer

Mr. Mills has 25 years of experience as a serial entrepreneur participating and leading a variety of ventures including software development, wetlands banking, medical devices, and portable storage units. His experience in fund raising and marketing provides the necessary expertise to raise needed capital, create strategic alliances and lead the company in a positive direction in order for OMT to aggressively pursue product and commercial development.

Advisory Board

Hamid Boulares, Ph.D.

Dr. Boulares is Associate Professor of Pharmacology and Experimental Therapeutics; received his Ph.D. from the University of Connecticut and completed Post-Doctoral training at Vanderbilt University. His research has contributed significantly to our understanding of the role of oxidative stress in asthma and atherosclerosis. His expertise in colon cancer research and the use of cell culture systems and animal models to study the intricate relation between poly(ADP) ribose polymerase1 (PARP-1) has been instrumental in improving the efficiency of Drs. Paul and Gould's efforts in developing TOL.


Jonathan S. Forester, M.D.

Dr. Forester practices family medicine in Pineville, LA. His strong interest in basic science and commitment to integrating the biological, clinical, and behevioral sciences into his practice has led to his national recognition as an authority in treating fibromyalgia, chronic fatigue, and chronic Lyme disease. Dr. Forester completed his undergraduate studies at Louisiana College and obtained his graduate degree from NLU School of Pharmacy, where he taught pharmacology lab and conducted research on dopamine and alcohol-induced sleep in rats. After receiving his M.D. from the Medical College of Georgia, he served in the United States Navy as a Lt. Commander with the U.S. Naval Security Group, and was awarded the Naval Achievement Medal by the Secretary of the Navy. Dr. Forester founded Christian Oasis, a non-profit ministry to help emotionally scarred people with or without substance abuse problems and is the author of the book, Conquering Chronic Fatigue: Answers to a Vastly Misunderstood Epidemic.


S. R. Levinson, Ph.D.

Dr. Levinson is Chief Science Officer and Vice President of Research for Biotricity Medical Inc. and Professor of Physiology and Biophysics at the University of Colorado School of Medicine. He has 37 years' experience as a professional scientist studying the principles and mechanisms of bioelectricity generation on which the EpiVolt (tm) biogenerator is based. He received his B.S. at the California Institute of Technology and his Ph.D. at the University of Cambridge. Dr. Levinson's research has contributed to our understanding about how molecules and cells produce and regulate bioelectricity. He has extensive experience as the principle investigator on numerous federal and private grants, including those from the National Institutes of Health, the National Science Foundation, National Multiple Sclerosis Society, Muscular Dystrophy Association, and Allergan, Inc. He is co-inventor of the biogenerator and has licensed antibody production technology to industry. This technology and his work on sodium channel physiology were instrumental in enabling Gould and Paul's initial observations that has led to the development of TOL.


Charles Nichols, Ph.D.

Dr. Nichols is Associate Professor of Pharmacology and Experimental Therapeutics; received his Ph.D. from Carnegie Mellon University, Pittsburgh, PA and completed Post-Doctoral training at Vanderbilt University. Dr. Nichols's research and discovery of serotonin 5-HT2A receptor activation effect on suppressing TNF-alpha-induced inflammation and has led to the development and submission of a U.S. Patent application. His expertise in cell culture technology has been instrumental in improving the efficiency of Drs. Paul and Gould's efforts in developing TOL. He has served on the Advisory Board of DAR Pharmaceuticals.


Augusto Ochoa, M.D.

Dr. Ochoa received his M.D. from the Universidad de Antioquia in Colombia. He completed his postdoctoral training at the Immunobiology Research Center at the University of Minnesota in Minneapolis, where he became an Assistant Professor. Dr. Ochoa has served as Head of the Immunotherapy Laboratory for the National Cancer Institute (NCI) from 1989 to 1996, and Head of the NCI Signal Transduction Laboratory from 1996 to 1997. He is currently Professor of Pediatrics, Adjunct Associate Professor of Biochemistry and the Director of the Stanley S. Scott Cancer Center at the LSU Health Sciences Center. He is an expert in the study of T-cell function, cytokine production, macrophage T-cell interaction, immune regulation, immune dysfunction and disease, as well as tumor immunology.


Austin J. Sumner, M.D.

Dr. Sumner is the former Richard M. Paddison Professor and Chairman of Neurology at Louisiana State University Health Sciences Center. He received his M.D. from the University of Otago. He received his specialty board equivalent as member of the Royal Australasian College of Physicians. He was awarded the Nuffield Foundation Postdoctoral Traveling Fellowship in Medicine which he took up at the National Hospital for Neurology and Neurosurgery, Queen Square, London, England. He was recruited from the University of Pennsylvania in Philadelphia and served as the department head of the department of neurology at the Louisiana State University Health Sciences Center from 1988 until 2007. Dr. Sumner has served as Director of the LSU Healthcare Network and as Vice-Chairman of the Board of Trustees of the Louisiana Chapter of the National Multiple Sclerosis Society. At a national level, he is a trustee of the American Academy of Neurology Foundation, past chairman of the American Board of Electrodiagnostic Medicine. Dr. Sumner's research interests focus on the diagnosis and treatment of peripheral neuropathies, neuromuscular diseases, multiple sclerosis, and clinical neurophysiology.

Advisory Consultant for Federal Grants and Compliance

Carol R. Scheman

Ms. Scheman received her B.A. from Boston University and an MSSA from Case Western Reserve University. She is an independent consultant working with the federal government, research universities and scientific societies. She served as senior vice president for external affairs of Northeastern University (2008-2009), reorganizing the university's external affairs capacity; and was previously the vice president for communications and external affairs at The Uniformed Services University (USU) of the Health Science, where she coordinated and directed relationships with the media, university publications and electronic communications, alumni, the Board of Regents, and communities, as well as governmental agencies, and the U.S. Congress. Previously, Ms. Scheman was vice president for government, community and public affairs at the University of Pennsylvania from September 1994 until July 2005, where she developed, coordinated and implemented activities and responses to public policy issues at the federal, state and local levels of government. In addition, Ms. Scheman worked closely with community leaders to enhance Penn's relationship with its neighbors. Earlier in her career, she was deputy commissioner of the U.S. Food and Drug Administration. She also served as director of federal relations at the Association of American Universities (AAU) for 13 years and then became vice president in 1991. She also worked as a legislative assistant on Capitol Hill. Since 2006, Carol has served as Secretary for the National Board of Learning Ally and serves on Learning Ally's Executive and Human Resources Committees.




Oleander Medical Technologies
Louisiana Emerging Technology Center
340 East Parker Center, Baton Rouge, LA 70803
Phone: (225) 413-7658

Targeted Osmotic Lysis and TOL are trademarks of Oleander Medical Technologies.
International patents pending.